Chung Hyunju, Seo Sanghee, Moon Minho, Park Seungjoon
Department of Pharmacology and Medical Research Center for Bioreaction to ROS and Biomedical Science Institute, Kyunghee University School of Medicine, Seoul 130-701, South Korea.
J Endocrinol. 2008 Sep;198(3):511-21. doi: 10.1677/JOE-08-0160. Epub 2008 Jun 9.
Only acylated ghrelin (AG) binds GH secretagog receptor 1a (GHS-R1a) and has central endocrine activities. An anti-apoptotic effect of AG in neuronal cells has recently been reported. However, whether there is a neuroprotective effect of unacylated ghrelin (UAG), the most abundant form of ghrelin in plasma, is still unknown. Therefore, we investigated whether UAG was neuroprotective against ischemic neuronal injury using primary cultured rat cortical neurons exposed to oxygen and glucose deprivation (OGD). Both AG and UAG inhibited OGD-induced apoptosis. Exposure of cells to the receptor-specific antagonist D-Lys-3-GHRH-6 abolished the protective effects of AG against OGD, whereas those of UAG were preserved, suggesting the involvement of a receptor that is distinct from GHS-R1a. Chemical inhibition of MAPK and phosphatidylinositol-3-kinase (PI3K) blocked the anti-apoptotic effects of AG and UAG. Ghrelin siRNA enhanced apoptosis either during OGD or even in normoxic conditions. The protective effects of AG and UAG were accompanied by an increased phosphorylation of extracellular signal-regulated kinase (ERK)1/2, Akt, and glycogen synthase kinase-3beta (GSK-3beta). Furthermore, treatment of cells with AG or UAG resulted in nuclear translocation of beta-catenin. In addition, both AG and UAG increased the Bcl-2/Bax ratio, prevented cytochrome c release, and inhibited caspase-3 activation. The data indicate that, independent of acylation, ghrelin can function as a neuroprotective agent that inhibits apoptotic pathways. These effects may be mediated via activation of the MAPK and PI3K/Akt pathways. Our data also suggest that PI3K/Akt-mediated inactivation of GSK-3beta and stabilization of beta-catenin contribute to the anti-apoptotic effects of ghrelin.
只有酰基化胃饥饿素(AG)能结合生长激素促分泌素受体1a(GHS-R1a)并具有中枢内分泌活性。最近有报道称AG在神经元细胞中具有抗凋亡作用。然而,血浆中最丰富的胃饥饿素形式——去酰基化胃饥饿素(UAG)是否具有神经保护作用仍不清楚。因此,我们使用原代培养的大鼠皮质神经元,使其暴露于氧糖剥夺(OGD)环境中,研究UAG是否对缺血性神经元损伤具有神经保护作用。AG和UAG均能抑制OGD诱导的细胞凋亡。用受体特异性拮抗剂D-Lys-3-GHRH-6处理细胞可消除AG对OGD的保护作用,而UAG的保护作用依然存在,这表明存在一种不同于GHS-R1a的受体参与其中。对丝裂原活化蛋白激酶(MAPK)和磷脂酰肌醇-3-激酶(PI3K)的化学抑制可阻断AG和UAG的抗凋亡作用。胃饥饿素小干扰RNA(siRNA)在OGD期间甚至在常氧条件下均可增强细胞凋亡。AG和UAG的保护作用伴随着细胞外信号调节激酶(ERK)1/2、蛋白激酶B(Akt)和糖原合酶激酶-3β(GSK-3β)磷酸化水平的升高。此外,用AG或UAG处理细胞可导致β-连环蛋白的核转位。另外,AG和UAG均能增加Bcl-2/Bax比值,阻止细胞色素c释放,并抑制半胱天冬酶-3活化。这些数据表明,胃饥饿素可独立于酰基化发挥神经保护剂的作用,抑制凋亡途径。这些作用可能是通过激活MAPK和PI3K/Akt途径介导的。我们的数据还表明,PI3K/Akt介导的GSK-3β失活和β-连环蛋白的稳定有助于胃饥饿素的抗凋亡作用。